Next-Gen Treatment
Tirzepatide Injections
The most effective weight loss medication in clinical history — up to 22% body weight reduction.
22%
Max weight loss
SURMOUNT
Clinical trial
Dual
Mechanism of action
Strongest Results Available
What is Tirzepatide?
Tirzepatide is the next generation of weight loss injection — a dual GIP/GLP-1 receptor agonist. Unlike Semaglutide, which targets only GLP-1 receptors, Tirzepatide simultaneously activates both GIP and GLP-1 receptors, producing dramatically enhanced weight loss.
In the landmark SURMOUNT-1 clinical trial, patients on the highest dose of Tirzepatide lost an average of 22.5% of their body weight — more than any weight loss medication ever studied.
$349/first month
$399/mo ongoing · Cancel anytime
30-day Tirzepatide supply (2.5mg)
Licensed provider consultation
Dual GIP/GLP-1 mechanism
Free shipping · Monthly check-in
Comparison
Semaglutide vs. Tirzepatide
Both are highly effective. Here is how they compare to help you and your provider choose the right one.
| Feature | Semaglutide | Tirzepatide ★ |
|---|---|---|
| Mechanism | GLP-1 only | GLP-1 + GIP (dual) |
| Avg. weight loss | ~15% | Up to 22% |
| Injection frequency | Weekly | Weekly |
| Starting dose | 0.25mg/week | 2.5mg/week |
| Starting price | $249/mo | $349/mo |
| Best for | First-time GLP-1 users | Maximum weight loss results |
| Clinical trial | STEP 1 | SURMOUNT-1 |